Cormorant Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $520M

Cormorant Pharmaceuticals General Information

Description

Provider of pharmaceutical services. The company primarily focuses on developing therapeutics and related services for cancer and other rare diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Karolinska Institute Science Park
  • Fogdevreten 2A, Stockholm
  • 171 65 Solna
  • Sweden
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Karolinska Institute Science Park
  • Fogdevreten 2A, Stockholm
  • 171 65 Solna
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cormorant Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 05-Jul-2016 $520M Completed Generating Revenue
1. Buyout/LBO Completed Generating Revenue
To view Cormorant Pharmaceuticals’s complete valuation and funding history, request access »

Cormorant Pharmaceuticals Patents

Cormorant Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201509812-D0 Cancer companion diagnostics Inactive 05-Jun-2015
US-20080118517-A1 Chemokine specific immunoglobulin for prevention and treatment of cell proliferative, skin, inflammatory and autoimmune disorders Active 16-Dec-2002
US-7622559-B2 Chemokine specific immunoglobulin for prevention and treatment of cell proliferative, skin, inflammatory and autoimmune disorders Inactive 16-Dec-2002
AU-2003299641-A1 Human monoclonal antibodies against interleukin 8 (il-8) Active 16-Dec-2002
AU-2003299641-B2 Human monoclonal antibodies against interleukin 8 (il-8) Inactive 16-Dec-2002 C07K16/244
To view Cormorant Pharmaceuticals’s complete patent history, request access »

Cormorant Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cormorant Pharmaceuticals Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Flerie Venture Capital Majority
To view Cormorant Pharmaceuticals’s complete investors history, request access »

Cormorant Pharmaceuticals Investments (2)

Cormorant Pharmaceuticals’s most recent deal was a Later Stage VC with Zai Lab for . The deal was made on 28-Jun-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zai Lab 28-Jun-2017 Later Stage VC Pharmaceuticals
Genmab (HuMax-IL8) 30-May-2012 Corporate Asset Purchase Buildings and Property
To view Cormorant Pharmaceuticals’s complete investments history, request access »

Cormorant Pharmaceuticals FAQs

  • When was Cormorant Pharmaceuticals founded?

    Cormorant Pharmaceuticals was founded in 2010.

  • Where is Cormorant Pharmaceuticals headquartered?

    Cormorant Pharmaceuticals is headquartered in Solna, Sweden.

  • What is the size of Cormorant Pharmaceuticals?

    Cormorant Pharmaceuticals has 2 total employees.

  • What industry is Cormorant Pharmaceuticals in?

    Cormorant Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Cormorant Pharmaceuticals a private or public company?

    Cormorant Pharmaceuticals is a Private company.

  • What is the current valuation of Cormorant Pharmaceuticals?

    The current valuation of Cormorant Pharmaceuticals is .

  • What is Cormorant Pharmaceuticals’s current revenue?

    The current revenue for Cormorant Pharmaceuticals is .

  • Who are Cormorant Pharmaceuticals’s investors?

    Flerie has invested in Cormorant Pharmaceuticals.

  • When was Cormorant Pharmaceuticals acquired?

    Cormorant Pharmaceuticals was acquired on 05-Jul-2016.

  • Who acquired Cormorant Pharmaceuticals?

    Cormorant Pharmaceuticals was acquired by Bristol-Myers Squibb.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process